Prostate Cancer

BNT211-01, a novel CAR-T cell therapy, was efficacious in treating patients with CLDN6-positive, relapsed/refractory solid cancers, according to a small clinical trial.

From actress Jane Fonda giving an update on her cancer, to a patient with leukemia proving he was at the Sept. 11 attacks in New York City with an old newspaper clipping, here’s what’s happening in the cancer space this week.

There’s a flip side to the trauma of cancer — a better appreciation of the small things in everyday life.

Even though I had no symptoms, my prostate cancer was caught thanks to frequent follow-ups with my doctor.

I recently was asked to speak at a banquet for my cancer center and saw that as a great opportunity to recognize those who cared for me.

From the death of a football Hall of Famer and a golf champion to actress and former Nickelodeon star Jennette McCurdy discussing her mother’s breast cancer in her memoir, “I’m Glad My Mom Died,” here’s what’s happening in the cancer space this week.

Radiotherapy with standard of care for the treatment of patients with low-burden metastatic prostate cancer had minimal effects on quality of life over a five-year follow-up period.

From ESPN analyst Dick Vitale announcing he is cancer-free months following a lymphoma diagnosis to a Speedo-clad race in South Africa to raise awareness for cancer, here’s what’s happening in the oncology space this week.

If approved, the Lynparza-based regimen would become the first combination of a PARP inhibitor and a hormonal agent for metastatic castration-resistant prostate cancer.

I was shocked at a recent doctor appointment when practically nobody in the office was wearing a mask.

Joseph Wood and his caregiver, Deborah Wood, provide advice for patients and caregivers with prostate cancer who may be in similar situations, and comment on the support they have received from their family and community.

Treatment with an investigational drug plus with Libtayo showed encouraging anti-tumor activity in patients with advanced metastatic castration-resistant prostate cancer, according to preliminary data from an early-phase trial.

Keytruda plus chemotherapy failed to best the chemotherapy docetaxel alone in patients with metastatic castration-resistant prostate cancer, according to findings of a study of more than 1,000 patients.

Joseph Wood and his wife and caregiver, Deborah, share their concerns and questions about radioligand therapy and how the COVID-19 pandemic has impacted their treatment experience.

The Food and Drug Administration approved oral Nubeqa plus the chemotherapy docetaxel for patients with metastatic hormone-sensitive prostate cancer.

Treatment with primary radiotherapy was linked to an increased risk for the development of secondary primary cancers among a large group of men with localized prostate cancer, according to recent study findings.

Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer (mCRPC).

Drs Matthew Rettig and Jeremie Calais explain what it means to be a part of a collaborative team and how communication plays a big role in patients receiving optimal treatment.

Cancer treatment-related osteoporosis caused me to shrink two inches.

TAVT-45, an easy-to-swallow drug that can be suspended in water or juice, is being studied for the treatment of patients with metastatic prostate cancer.

Joseph Wood details his treatment journey with metastatic castration-resistant prostate cancer (mCRPC) and how the journey has impacted his wife and caregiver, Deborah Wood.

Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC).

As I reflect on cancer survivorship, I notice how important the camraderie with fellow survivors is.

Dr Jeremie Calais talks about the emergence and importance of PSMA-targeted radioligand therapy.

Dr Matthew Rettig reviews the front-line treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) and what factors are considered when choosing appropriate treatment.

While my wife has been an amazing caregiver throughout my cancer experience, I realized that it was not fair for her to continually be on the receiving end of all my negative emotions.

Joseph Wood, a patient, and Deborah Wood, Joseph’s wife and caregiver, talk about Joseph’s prostate cancer diagnosis and Deborah explains her role as a caregiver.

Jeremie Calais, MD, comments on how PSMA PET scans have changed the treatment landscape for patients with mCRPC and describes the process for obtaining a PSMA PET scan, including what patients should know before, during and after the scan.

Here is a roundup of cancer treatments that were approved by the FDA in the spring of 2022 that patients may have missed.

Looking back, perhaps a poem could have helped me tell my family about my cancer diagnosis.